Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) AI-Powered Stock Analysis
See how Bicara Therapeutics Inc. Common Stock scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
BCAX●NASDAQ
HealthcareBiotechnology
$22.01
$0.63(2.78%)
U.S. Market opens in 5h 55m
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerBicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) Stock Overall Grade
Bicara Therapeutics Inc. Common Stock's grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Bicara Therapeutics Inc. Common Stock's overall NASDAQ stock rating.
Forecast
AScore
89/100Financial Growth
CScore
40/100Fundamental Growth
CScore
45/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
B+Score
71/100Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) AI-Powered Stock Analysis
On the NASDAQ, BCAX demonstrates Good performance with an overall Forecast Score of 89/100 (A), reflecting high confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (45/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (71/100, B+) suggests High divergence in outlook.(NASDAQ: BCAX) Component Analysis Explained
Understand the key factors behind each Bicara Therapeutics Inc. Common Stock (NASDAQ: BCAX) stock grade, including financials, comparisons, and forecasts.